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Introduction
The role of estrogen in cardiovascular disease and its risk factors has been intensively investigated for many years. Initially it was thought that estrogen protects against cardiovascular disease because women have lower cardiovascular disease rates than men and the menopause precedes an increase in cardiovascular deaths. However, randomized controlled trials (RCTs) suggests that hormone replacement therapy (HRT) has little overall effect on cardiovascular disease or its risk factors but decreases LDL-cholesterol slightly (1), decreases diabetes and increases the risk of thrombosis and stroke (2) . Nevertheless, findings from these RCTs have been contested (3) , and the possibility that estrogens have some cardiovascular benefits remains a topic of active experimental investigation (4) . First, some hormone replacement trials mainly used estrogen and progestin, whose effects may differ from estrogen alone (2) . For example in the Women's Health Initiative (WHI) trial, estrogen and progestin together may increase the risk of ischemic heart disease whereas estrogen only had no effect (2) . Second, the effect of estrogen on cardiovascular risk may depend on other factors, such as timing of HRT initiation (4, 5) or the presence of atherosclerosis, i.e., when atherosclerosis is absent estrogen protects but when atherosclerosis is present estrogen is detrimental (6) . Given the risk of breast cancer and venous thrombosis from estrogen administration, further major RCTs of estrogen are unlikely, but the role of estrogen in cardiovascular disease remains an important topic relevant to the widespread use of oral contraceptives including estrogen. In this situation replication, or otherwise, using a different approach can make a key contribution. In this study, for the first time, we used a separate sample Mendelian randomization analysis to assess the lifelong effect of estrogen on cardiovascular disease risk factors, overall and in women without cardiovascular disease.
Mendelian randomization analysis, i.e., instrumental variable analysis with genetic instruments, is increasingly used to evaluate the causal role of risk factors in disease, particularly when RCTs are unavailable. Mendelian randomization may also enable assessment of the effects of endogenous rather than exogenous exposure, which may differ, because Mendelian randomization tests a causal pathway while an RCT tests an intervention which can have unknown pleiotropic effects (7) . Genetic polymorphisms associated with the exposure are randomly allocated during conception, so this resembles the randomization process in RCTs and hence is less susceptible to confounding (8) . Mendelian randomization analyses have clarified the role of many factors in cardiovascular disease etiology, such as C reactive protein (9).
However, a conventional Mendelian randomization analysis is sensitive to measurement error of the exposure, which may lead to inflated estimates (10) . Separate sample Mendelian randomization analysis, where a genetic prediction rule is generated in a sample less susceptible to measurement error, may alleviate this problem (11) . We have successfully implemented this approach to examine the effect of testosterone on cardiovascular disease risk factors and of testosterone and estrogen on inflammation in older people (12) (13) (14) . In this study, we examined the relation of lifelong exposure to estrogen with cardiovascular disease risk factors using a Mendelian randomization analysis among Southern Chinese women to clarify the role of lifelong estrogen exposure in health. 
Materials and methods

Sources of data
DNA extraction and SNP analysis
DNA was extracted using QIAamp DNA Blood Midi Kit (Catalog No.51185) for fresh blood in Hong Kong, phenol-chloroform extraction for fresh blood in GBCS and magnetic bead extraction for previously stored specimens in GBCS (17) . SNPs were selected from genes (ESR1, ESR2 and CYP19A1) (18-21) functionally relevant to estradiol or breast cancer, with minor allele frequency >5% in Chinese (22) . Five SNPs (rs2175898 from ESR1, rs1256030 and rs1256031
from ESR2, and rs10046 and rs1008805 from CYP19A1) were analyzed at the Centre for Genomic Sciences of the University of Hong Kong, for the Hong Kong sample, and a commercial company (Beijing Capital Bio Corporation) in Beijing, for the GBCS sample, using a Mass ARRAY system (Sequenom, San Diego, California). For DNA quality analysis we used spectrophotometry for most of the samples and gel electrophoresis for four duplicate check controls and six randomly selected samples in each DNA sample plate. The determined sample concentration and A260/280 ratios were 10-20ng/uL and 1.7-2.0, respectively. A call rate <80% was considered failure. All SNPs passed with a call rate >95%.
Exposure
The exposure was genetically predicted log 17β-estradiol (pmol/L).
Outcome
The outcomes were systolic and diastolic blood pressure, LDL-cholesterol, HDL-cholesterol, triglycerides, glucose, body mass index, waist hip ratio, waist circumference, and Framingham score. The Framingham score overestimates absolute risk of cardiovascular disease in Chinese populations (23) , but provides a risk ranking. The Framingham score was calculated from age, LDL-cholesterol, HDL-cholesterol, systolic blood pressure, diastolic blood pressure, diabetes (fasting plasma glucose≥7.0mmol/L, previous diagnosis or use of anti-diabetic medication) but excluded smoking to assess cardiovascular disease risk reflected by biological factors which provides more mechanistic information and is assessed more precisely.
Statistical analysis
In the sample of young Chinese women from Hong Kong, we established genetic predictors of log 17β-estradiol based on 2 SNPs from stepwise linear regression starting with 5 SNPs with replication in 1,000 bootstrapping samples, as described previously (13) . In the GBCS sample, we tested for Hardy-Weinberg equilibrium at the SNP locus on a contingency table of observed-versus-predicted frequencies with an exact test. We used ANOVA to assess whether genetically predicted log 17β-estradiol was associated with potential confounders. We used separate sample instrumental variable analysis to estimate the association of log 17β-estradiol with cardiovascular risk factors and Framingham score in the sample of older Chinese women from GBCS by using suest (seemingly unrelated regression command in Stata) to generate the Wald estimates from the ratio of the association of genetic determinants of log 17β-estradiol with cardiovascular risk factors and Framingham score in GBCS and the association of genetic determinants of log 17β-estradiol with log 17β-estradiol in the sample of young women (24) . Figure 1 shows the flow chart of the study.
Sensitivity analyses
Given the hypothesis that estrogen may have a different effect depending on cardiovascular disease status, we repeated the analyses by restricting the samples without self-reported history of cardiovascular diseases (ischemic heart disease, stroke/ transient ischemic attack, angina, myocardial infarction, valvular heart disease or peripheral vascular disease). We did not include rheumatic heart disease because it has an infectious origin different from other types of cardiovascular disease (25) .
All statistical analyses were conducted using Stata 13.1 (StataCorp LP, College Station, Texas, USA).
Results
Among the young Chinese woman samples (n=236, one participant was excluded because of an invalid 17β-estradiol value). The F statistic for the regression on log 17β-estradiol on genetic score was 13. (Table 3) .
Discussion
To date, this is the first study using Mendelian randomization analysis to examine the role of estrogen in traditional cardiovascular disease risk factors. Using a study design less susceptible to confounding than observational studies which also allows examination of the effect of lifelong (26, 27) . Lastly, we did not find any association of estrogen with predicted risk of future ischemic heart disease events, proxied by Framingham score, consistent with the WHI findings in the estrogen alone treatment arm (28).
Although we used a separate sample Mendelian randomization analysis which is less susceptible to confounding and allows estimation of the effect of lifelong estrogen exposure, limitations existed. First, cardiovascular events are not available, so estrogen could protect against cardiovascular events by pathways other than those examined here. Our previous study showed estrogen reduced the inflammation implicated in cardiovascular disease (13) . Estrogen might also reduce testosterone (29) , which could be beneficial. However, estrogen also promotes thrombosis that can provoke cardiovascular events (30) . Second, although a separate sample
Mendelian randomization analysis may be less susceptible to measurement of the exposure compared to a conventional Mendelian randomization analysis, we are unable to assess if the instrument violates the exclusion restriction criteria, i.e., that the genetic polymorphisms only affected cardiovascular disease risk via estrogen, as we do not have estrogen polymorphisms, and estrogen and cardiovascular risk factors were all measured in the same dataset. However, the estrogen related genetic polymorphisms are in the sex-steroid pathway, and genetically predicted estrogen was unrelated to testosterone in the sample of young women (13) . Third, we did not use estrogen polymorphisms from genome wide association studies (GWAS), because no such studies have reliably identified estrogen related genetic polymorphisms in Chinese women.
Therefore, we have established our own genetic prediction rule in a young Chinese women sample using stepwise regressions and bootstrapping methods, as described previously. (13) Fourth, Mendelian randomization analysis may be susceptible to confounding by population stratification but the participants from this study had the same genetic origin. Fifth, although our study is largely in line with the results from RCTs of HRT but the confidence intervals are wide, so we cannot rule out small effects on glucose and LDL cholesterol as seen in RCTs (31). Our study was powered to detect a change of 0.23 standard deviation in cardiovascular disease risk factors, for example a blood pressure change of 5 mmHg per increase in one log unit change in estrogen. As such our study was underpowered to detect small effects of estrogen that could be important to population health, although less clinically relevant. Sixth, we used genetic determinants of estrogen in young women to avoid reverse causality, however effects of genetic determinants could vary with age. Lastly, our study only focused on estrogen and hence our result could not directly infer the relation of combined treatment (i.e. estrogen and a progestin) on cardiovascular health. Furthermore, this makes comparison of our results with previous RCTs of HRT more difficult because not all trials had an estrogen only arm. However, this may also imply our study adds to our understanding of the effect of estrogen alone on cardiovascular risk factors.
Our study provides an example of a feasible method of implementing Mendelian randomization studies cost-effectively when GWAS of uncommonly measured exposures are not available. It also confirms a fairly minor role of estrogen in cardiovascular disease risk factors, consistent with the minor inflection in cardiovascular disease rates at the menopause (32). Our study does not suggest that the effect of estrogen on cardiovascular disease varies by disease status. As such, observations concerning differences by timing of HRT initiation (5) might be a false positive to which post-hoc analyses are susceptible, and would need confirmation from studies specifically designed to examine the timing hypothesis (4). Our findings are not consistent with observational studies of HRT, but these are known to be biased by HRT users being of higher socio-economic status and more health conscious than non-users (33) (34) (35) . Our results might also be relevant to the much more common estrogen exposure from the oral contraceptive pill, whose effects on cardiovascular events have never been assessed in an RCT (36) . Observational studies have found combined contraceptive pills (i.e. estrogen and progestin) associated with higher blood pressure, LDL cholesterol, higher risk of thrombosis, and lower HDL cholesterol, which could be due to the estrogen or progestin or residual confounding (36) . However, we cannot assess this possibility because we do not have these events, or their biomarkers, such as thrombin.
Our study provides new evidence concerning the relation of estrogen with cardiovascular disease risk factors using a separate sample Mendelian randomization analysis. No evidence supporting potential cardio-protection by estrogen or evidence for the timing hypothesis was found.
However, given the limitations of this study, a larger Mendelian randomization analysis with cardiovascular outcomes may help clarify the role of estrogen in cardiovascular disease in a timely manner, with corresponding implications for public health, clinical practice and etiology concerning estrogen exposures such as HRT and oral contraceptives.
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